Global Pharma Streamlines MLR Process to Accelerate Time to Market

A global pharmaceutical leader in Neurology, managing over 20 brands across 100+ countries.

MLR review inefficiencies were slowing down content readiness and market responsiveness.

Content Volume Tripled: Changes in content consumption trends led to a 3X increase in materials needing MLR approval.
Review Bottlenecks: Existing MLR capacity couldn’t keep up, causing delays and frequent non-compliance with turnaround SLAs.
Business Impact of Delays: Slower content approvals meant missed opportunities in brand promotion and HCP engagement.
Manual, Error-Prone Workflows: Without automation or standardization, 20% of assets had errors post-production, requiring rework and risking compliance.

Comprehensive process diagnostics: Via documentation review, interviews and benchmarking against best-in-class industry practices.
Gap analysis: Uncovered 20+ gaps identified across material quality, review efficiency, people, and scalability.
Strategic Roadmap: Delivered 15+ actionable recommendations, balancing quick wins with long-term improvements.

Faster time to market leading to reduction in business opportunity cost
Reduction in review cycles due to improved quality of assets
Elimination of errors in postproduction files
Reduction in review costs due to improved productivity and leaner content review